Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Advanced Solid Tumor BRAF Gene Mutation BRAF Gene Alteration MEK Mutation MEK Alteration MAP2K1 Gene Mutation MAP2K1 Gene Alteration MAP2K2 Gene Mutation MAP2K2 Gene Alteration atypical BRAF, non-V600 Neoplasms Ulixertinib Physician's Choice
Lead Scientist at University of California Health
- Shumei Kato, MD (ucsd)
Associate Clinical Professor, Medicine. Authored (or co-authored) 86 research publications.